Augmedics, a pioneer in augmented reality surgical image guidance, announced that Raj Asarpota has been appointed executive vice president and chief financial officer, effective September 15, 2021. In this role, Asarpota will lead Augmedics’ global finance organization and will be responsible for accounting, treasury, financial planning and analysis, tax, and investor relations. Asarpota’s CFO appointment and extensive experience in the medical device arena will complete the Augmedics senior leadership team. Nissan Elimelech, Augmedics’ chief executive officer said:
“I am pleased to welcome Raj Asarpota to our leadership team. His extensive experience in leading the financial operations of spine-focused medical device business – as well as driving successful M&A transactions – will make him an immediate asset to the future of the Augmedics business. He, as well as his tenure, are the perfect addition to our already incredible team.”
Mr. Asarpota joins Augmedics after his most recent role at ApiJect as executive vice president, chief financial officer and head of technology. ApiJect Systems America, Inc., is a medical technology company that seeks to revolutionize how medicines and vaccines are filled, finished and delivered. Prior to ApiJect, Asarpota served as executive vice president and chief financial officer with NuVasive, a global public company and leader in minimally invasive, procedurally integrated spine solutions, where he was involved with supporting the company’s growth strategy through innovation and operational excellence. Mr. Asarpota said:
“I am incredibly excited to partner with Nissan and the management team to drive Augmedics’ revolutionary technology to significantly improve outcomes for patients and surgeons along with positioning the company for continued growth and value creation.”
Prior to NuVasive, he spent two years in the private equity space at Imaging Advantage and Cole Parmer as executive vice president and chief financial officer. Imaging Advantage was acquired by Envision in 2015. In 2014, he served as the executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6B transaction. Asarpota also spent a decade at Life Technologies, a global life sciences company where he was responsible for helping scale the organization, driving growth through organic and M&A channels. During his tenure, the company revenue grew from approximately $1B to more than $4B in 2014, leading to the company’s sale to Thermo Fisher for $13.6 billion that year. Prior to Life Technologies, Asarpota spent 11 years at GE in several finance leadership roles.